US Diabetes Drug Market, Dosage, Price, Sales Insight 2021 - 2026

Abstract
"US Diabetes Drug Market, Dosage, Price, Sales Insight 2021 - 2026" Report Highlights:

• US Diabetes Drugs Market & Clinical Trial Insight
• Comprehensive Insight On Approved Diabetes Drugs Price & Dosage Analysis For US Market
• Diabetes Drugs Patent Timeline
• Dosage, Formulation, Patent, Pricing Insight by Drug Class
• 500 Page Data & Analysis On All Approved Drugs In Market

The US pharmaceutical market will continue to see a focus on the transformation of the diabetes market at an unprecedented rate. The overall transformation led down by the country is about using the therapeutics platform symbiotically as well as strategically to extract and unravel hidden information associated with the disease. Diabetes market in the country is fast becoming the largest contributor to the US pharmaceutical market and hundreds of biotech and bio-pharma companies are building novel strategies for the future. The US diabetes market is believed to be the outcome of the advancement in the therapeutics sector as arrival of hundreds of potent drugs have significantly improved the total patient outcomes. Over the past few years, much work and extensive investment have been done in the diabetes research and development across industry and academia, resulting in a complete focused area for major key players.

The US over the past few years has also observed large number of diabetes cases, thus making the market deliver opportunities with respect to diabetes disease targets with high premium deals. With more than hundreds of clinical compounds in development (which consists of approximately half of the global clinical compounds), the US is also considered as a global leader in the clinical platform associated with the market. In addition, the abundant organic research and development at different clinical-stage biotechs and large bio-pharmaceutical companies is also observed to unbox spate of multibillion dollar diabetes focused acquisitions and partnerships, thus making the US observe a market growth rate that is splendid.

The high clinical promising prospects is believed to be sufficiently transformative in inclining the country towards receiving success over the next several decades. Specific trends followed in the country for the market such as high value deals are observed to get repeated in the future years, thus assessing the future shape of the market in delivering healthcare benefits to global patients. The current success rate in diabetes, with an average launch timeline of several drugs is observed to make up over a large percentage of global percentage of diabetes drugs launched every year.

As per the "US Diabetes Drug Market, Dosage, Price, Sales Insight 2021 - 2026" report findings related to US diabetes drug market, it is concluded that the US diabetes market will make the future of the global diabetes market more intense. With more than several clinical compounds in development, the US diabetes market is believed to provide some novel assets to the global market, thus captivating a phase for market that is tremendous and capable of growing at a double-digit compound annual growth rate. The overall strategic alliances adopted by major and local drug makers in the country are also leading to the biosynthesis of the drugs capable of holding trending opportunities for the patients. Despite of having a rigid competition from other pharmaceutical market such as Europe, the stages of development of the market followed by the country researchers are bound to fetch more latest innovation and attention from other leaders. It is believed that the market in the US due to trending opportunities will witness significant growth rate as well as speedy expansion.

Content
1. US Diabetes Drugs Market - Prevalence & Statistics

2. US Diabetes Drugs Market Overview
2.1 Current Market Scenario
2.2 Clinical Trials Landscape

3. US Insulins Based Drugs - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
3.1 Insulin Lispro
3.2 Insulin Glargine
3.3 Insulin Aspart
3.4 Insulin Detemir
3.5 Insulin Regular
3.6 Insulin Aspart / Insulin Aspart Protamine
3.7 Insulin Degludec
3.8 Insulin Glulisine
3.9 Insulin Inhalation
3.10 Insulin Isophane / Insulin Regular
3.11 Insulin Isophane
3.12 Insulin Lispro / Insulin Lispro Protamine

4. Non-Sulfonylureas - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
4.1 Metformin

5. Sulfonylureas - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
5.1 Chlorpropamide
5.2 Glimepiride
5.3 Glyburide
5.4 Glipizide
5.5 Tolazamide
5.6 Tolbutamide

6. Thiazolidinediones - Branded & Generic Availability, Dosage, Patent & Price
Analysis
6.1 Pioglitazone
6.2 Rosiglitazone

7. Incretin mimetics - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
7.1 Liraglutide
7.2 Exenatide
7.3 Semaglutide
7.4 Dulaglutide
7.5 Lixisenatide

8. Dipeptidyl peptidase 4 inhibitors - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
8.1 Sitagliptin
8.2 Saxagliptin
8.3 Linagliptin
8.4 Alogliptin

9. SGLT-2 inhibitors - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
9.1 Canagliflozin
9.2 Ertugliflozin
9.3 Empagliflozin
9.4 Dapagliflozin


10. Meglitinides - Branded & Generic Availability, Dosage, Patent & Price Analysis
10.1 Repaglinide
10.2 Nateglinide

11. Alpha-glucosidase inhibitors - Branded & Generic Availability, Dosage, Patent & Price Analysis
11.1 Miglitol
11.2 Acarbose

12. Combinational - Branded & Generic Availability, Dosage, Patent, Price & Sales Analysis
12.1 Metformin/Sitagliptin
12.2 Glimepiride/Pioglitazone
12.3 Glyburide/Metformin
12.4 Dapagliflozin/Metformin
12.5 Empagliflozin/Metformin
12.6 Glipizide/Metformin
12.7 Linagliptin/Metformin
12.8 Metformin/Pioglitazone
12.9 Metformin / Saxagliptin (Kombiglyze XR)
12.10 Alogliptin / Metformin (Kazano)
12.11 Alogliptin / Pioglitazone (Oseni)
12.12 Canagliflozin/Metformin (Invokamet/ Invokamet XR)
12.13 Dapagliflozin / Saxagliptin (Qtern)
12.14 Empagliflozin / Linagliptin / Metformin

12.15 Empagliflozin / Linagliptin (Glyxambi)
12.16 Ertugliflozin / Metformin (Segluromet)
12.17 Ertugliflozin / Sitagliptin (Steglujan)


13. Other Antidiabetic Drugs - Branded & Generic Availability, Dosage, Patent & Price Analysis
13.1 Bromocriptine (Cycloset)
13.2 Colesevelam (Welchol)
13.3 Pramlintide (Symlin)

14. Compititive Landscape
14.1 AstraZeneca
14.2 Boehringer Ingelheim
14.3 Daiichi Sankyo
14.4 Eli Lilly
14.5 GSK
14.6 Janssen Pharma
14.7 Merck
14.8 Novartis
14.9 Novo Nordisk
14.10 Pfizer
14.11 Sanofi
14.12 Takeda

List of Figures
Figure 1-1: US – Estimated Diabetic Population (Million), 2019, 2025, 2030 & 2045
Figure 1-2: US – Undiagnosed & Diagnosed Diabetic Population (Million), 2019
Figure 1-3: US – Undiagnosed & Diagnosed Diabetic Population (%), 2019
Figure 1-4: US – Estimated Diabetic Prevalence Rate (%), 2019, 2025, 2030 & 2045
Figure 1-5: US – Diabetic Population by Type (Million), 2019
Figure 1-6: US – Diabetic Population by Type (%), 2019
Figure 1-7: US – Type 1 Diabetes Cases by Age (Million), 2019
Figure 1-8: US – Maximum Diabetic Prevalence Rate by States (%), 2020
Figure 1-9: US – Minimum Diabetic Prevalence Rate by States (%), 2020

Figure 2-1: US – Diabetes Drug Market Opportunity (US$ Billion), 2019 - 2026
Figure 2-2: Global – Diabetes Drug Market Opportunity (US$ Billion), 2019 - 2026
Figure 2-3: North America – Diabetes Drug Market Size US v/s Others (US$ Billion), 2020
Figure 2-4: US – Insulin Market Opportunity (US$ Billion), 2019 - 2026
Figure 2-5: US – Diabetes Drug Market by Product (US Billion), 2020
Figure 2-6: US – Diabetes Drug Market by Product (%), 2020
Figure 2-7: US - Number of Diabetes Drug Clinical Pipeline by Phase, 2021 - 2026
Figure 2-8: US - Number of Diabetes Drugs in Clinical Pipeline by Drug Class, 2021 - 2026
Figure 2-9: US - Number of Diabetes Drugs in Clinical Pipeline by Organization, 2021 - 2026
Figure 2-10: US - Number of Diabetes Drugs in Clinical Pipeline by Patient Segment, 2021 - 2026

Figure 3-1: US – Insulin Lispro FDA Approval & Patent Expiration Year
Figure 3-2: US – FDA Approval History by Brand Name
Figure 3-3: Humalog – Cost of Supply of 3ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-4: Humalog – Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021

Figure 3-5: Humalog KwikPen – Cost of 15ml & Per Unit Cost of Injectable Solution (US$), February’2021
Figure 3-6: Humalog KwikPen – Cost of 6ml & Per Unit Cost of Subcutaneous Solution (US$), February’2021
Figure 3-7: Admelog – Cost of Supply of 3ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-8: Admelog – Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-9: Lyumjev - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-10: Humalog Junior KwikPen - Cost of Supply of 15ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-11: Insulin Lipro - Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-12: Insulin Lispro – Price Per ml By Brand Name (US$)
Figure 3-13: Global – Humalog Annual Sales (US$ Million), 2017-2020
Figure 3-14: Global – Admelog Annual Sales (US$ Million), 2018 & 2019
Figure 3-15: US - Admelog Annual Sales (US$ Million), 2018 & 2019
Figure 3-16: Admelog – Annual Sales by Region (US$ Million), 2019
Figure 3-17: Admelog – Annual Sales by Region (%), 2019
Figure 3-18: Global – Admelog Quarterly Sales (US$ Million), 2019
Figure 3-19: US – Admelog Quarterly Sales (US$ Million), 2019
Figure 3-20: Global – Admelog Quarterly Sales (US$ Million), 2020
Figure 3-21: US – Insulin Glagrine FDA Approval & Patent Expiration Year
Figure 3-22: Insulin Glagrine – FDA Approval History by Brand
Figure 3-23: Lantus – Cost of Supply of 10ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 3-24: Basaglar – Cost of Supply of 15ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 3-25: Toujeo - Cost of Supply of 4.5ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 3-26: Lantus Solostar- Cost of Supply of 15ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 3-27: Semglee - ost of Supply of 10ml & Per Unit Price of Subcutaneous Solution (US$), February’2021

Figure 3-28: Global – Lantus Annual Sales (US$ Million), 2017-2019
Figure 3-29: US - Lantus Annual Sales (US$ Million), 2017- 2019
Figure 3-30: Lantus – Annual Sales by Region (US$ Million), 2019
Figure 3-31: Lantus – Annual Sales by Region (%), 2019
Figure 3-32: Global – Lantus Quarterly Sales (US$ Million), 2019
Figure 3-33: US –Lantus Quarterly Sales (US$ Million), 2019
Figure 3-34: Global – Lantus Quarterly Sales (US$ Million), 2020
Figure 3-35: US - Lantus Quarterly Sales (US$ Million), 2020
Figure 3-36: Lantus – Annual Sales by Region (%), 2020
Figure 3-37: Global –Basaglar Annual Sales (US$ Million), 2017-2020
Figure 3-38: Global – Toujeo Annual Sales (US$ Million), 2017-2019
Figure 3-39: US - Toujeo Annual Sales (US$ Million), 2017- 2019
Figure 3-40: Toujeo – Annual Sales by Region (US$ Million), 2019
Figure 3-41: Toujeo – Annual Sales by Region (%), 2019
Figure 3-42: Global – Toujeo Quarterly Sales (US$ Million), 2019
Figure 3-43: US – Toujeo Quarterly Sales (US$ Million), 2019
Figure 3-44: Global – Toujeo Quarterly Sales (US$ Million), 2020
Figure 3-45: US - Toujeo Quarterly Sales (US$ Million), 2020
Figure 3-46: Toujeo – Annual Sales by Region (%), 2020
Figure 3-47: US – Insulin Aspart FDA Approval & Patent Expiration Year
Figure 3-48: US – FDA Approval History by Brand
Figure 3-49: Novolog – Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), Fbruary’2021
Figure 3-50: Novolog PenFill – Cost of Supply of 15ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-51: Fiasp – Cost of Supply of 15ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-52: Fiasp – Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-53: Insulin Aspart – Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-54: Global – Fiasp Annual Sales (US$ Million), 2018-2020
Figure 3-55: US - Fiasp Annual Sales (US$ Million), 2018-2020
Figure 3-56: Fiasp – Annual Sales by Region (%), 2019
Figure 3-57: Fiasp – Annual Sales by Region (%), 2020

Figure 3-58: US – Insulin Detemir FDA Approval & Patent Expiration Year
Figure 3-59: Levemir – Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-60: Global – Levemir Annual Sales (US$ Million), 2018-2020
Figure 3-61: US - Levemir Annual Sales (US$ Million), 2018-2020
Figure 3-62: Levemir – Annual Sales by Region (%), 2019
Figure 3-63: Levemir – Annual Sales by Region (%), 2020
Figure 3-64: US – Insulin Regular FDA Approval & Patent Expiration Year
Figure 3-65: Insulin Regular – FDA Approval Year by Brand
Figure 3-66: Humulin – Cost of Supply of 3ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-67: Humulin – Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-68: Novolin – Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-69: Humulin R U-500 – Cost of Supply of 20ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-70: Humulin KwikPen– Cost of Supply of 6ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 3-71: Myxredlin– Cost of Supply of 1200ml & Per Unit Price of Intravenous Solution (US$), February’2021
Figure 3-72: Global – Humulin Annual Sales (US$ Million), 2017-2020
Figure 3-73: Novolog Mix 70/30 - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 3-74: Novolog Mix 70/30 FlexPen - Cost of Supply of 15ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 3-75: Insulin Aspart/Insulin Aspart Protamine - Cost of Supply of 15ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 3-76: Insulin Aspart/Insulin Aspart Protamine - Cost of Supply of 10ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 3-77: Global – NovoMix Annual Sales (US$ Million), 2018-2020
Figure 3-78: US - NovoMix Annual Sales (US$ Million), 2018-2020
Figure 3-79: NovoMix – Annual Sales by Region (%), 2019
Figure 3-80: NovoMix – Annual Sales by Region (%), 2020
Figure 3-81: US – Insulin Degludec FDA Approval & Patent Expiration Year

Figure 3-82: Tresiba- Cost of Supply of 10ml & Per Unit Price of 100units/ml Subcutaneous Solution (US$), February’2021
Figure 3-83: Tresiba- Cost of Supply of 15ml & Per Unit Price of 100units/ml Subcutaneous Solution (US$), February’2021
Figure 3-84: Tresiba- Cost of Supply of 9ml & Per Unit Price of 200units/ml Subcutaneous Solution (US$), February’2021
Figure 3-85: Global – Tresiba Annual Sales (US$ Million), 2018-2020
Figure 3-86: US - Tresiba Annual Sales (US$ Million), 2018-2020
Figure 3-87: Tresiba – Annual Sales by Region (%), 2019
Figure 3-88: Tresiba – Annual Sales by Region (%), 2020
Figure 3-89: US – Insulin Glusine FDA Approval & Patent Expiration Year
Figure 3-90: US – FDA Approval Year by Brand
Figure 3-91: Apidra – Cost of Supply of 10ml & Per Unit Price of injectable solution (US$), February’2021
Figure 3-92: Global – Apidra Annual Sales (US$ Million), 2017-2019
Figure 3-93: US - Apidra Annual Sales (US$ Million), 2017- 2019
Figure 3-94: Apidra – Annual Sales by Region (US$ Million), 2019
Figure 3-95: Apidra – Annual Sales by Region (%), 2019
Figure 3-96: Global – Apidra Quarterly Sales (US$ Million), 2019
Figure 3-97: US – Apidra Quarterly Sales (US$ Million), 2019
Figure 3-98: Global – Apidra Quarterly Sales (US$ Million), 2020
Figure 3-99: US - Apidra Quarterly Sales (US$ Million), 2020
Figure 3-100: Apidra – Annual Sales by Region (%), 2020
Figure 3-101: Afrezza – Cost of Supply of 90 Powders & Per Unit Cost of 4 Units Powder (US$), February’2021
Figure 3-102: Afrezza – Cost of Supply of 90 Powders & Per Unit Cost of 8 Units Powder (US$), February’2021
Figure 3-103: Afrezza – Cost of Supply of 90 Powders & Per Unit Cost of 12 Units Powder (US$), February’2021
Figure 3-104: Insulin Isophane/Insulin Regular – FDA Approval Year by Brand
Figure 3-105: Humulin 70/30 – Cost of Supply of 10ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 3-106: Humulin 70/30 – Cost of Supply of 3ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021


Figure 3-107: Humulin 70/30 Pen – Cost of Supply of 15ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 3-108: Novolin 70/30 – Cost of Supply of 10ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 3-109: ReliON – Cost of Supply of 10ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 3-110: Insulin Isophane – FDA Approval Year by Brand
Figure 3-111: Humulin N – Cost of Supply of 3ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 3-112: Humulin N – Cost of Supply of 10ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 3-113: Humulin N Pen – Cost of Supply of 15ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-114: Novolin N – Cost of Supply of 10ml & Per Unit Price of Injectable Solution (US$), February’2021
Figure 3-115: Humalog Mix 50/50 – Cost of Supply of 10ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 3-116: Humalog Mix 50/50 Pen – Cost of Supply of 15ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 3-117: Humalog Mix 75/25 – Cost of Supply of 10ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021
Figure 3-118: Humalog Mix 50/50 Pen – Cost of Supply of 15ml & Per Unit Price of Subcutaneous Suspension (US$), February’2021

Figure 4-1: Metformin – FDA Approval & 1st Generic Approval Year
Figure 4-2: Metformin – FDA Approval Year by Brand
Figure 4-3: US – Glumetza Patent Approval & Expiration Year
Figure 4-4: US – Riomet Patent Approval & Expiration Year
Figure 4-5: Glumetza – Cost of Supply of 100 Tablets & Per Unit Price of 500mg Oral Tablet (US$), February’2021
Figure 4-6: Glumetza – Cost of Supply of 90 Tablets & Per Unit Price of 1000mg Oral Tablet (US$), February’2021
Figure 4-7: Glumetza – Per Unit Cost of 500mg & 100mg Oral Tablet (US$), February’2021
Figure 4-8: Glumetza – Maximum & Minimum Recommended Dose (mg)

Figure 4-9: Riomet – Cost of Supply of 118ml & Per Unit Price of Oral Soltuion (US$), February’2021
Figure 4-10: Riomet – Cost of Supply of 473ml & Per Unit Price of Oral Soltuion (US$), February’2021
Figure 4-11: Riomet – Maximum & Minimum Recommended Dose (mg)
Figure 4-12: Riomet – Cost of Supply of 118ml & 473ml of Oral Soltuion (US$), February’2021
Figure 4-13: Metformin – Cost of Supply of 30, 90 & 100 Oral Tablets (500mg) (US$), February’2021
Figure 4-14: Metformin – Cost of Supply of 30, 90 & 100 Oral Tablets (850mg) (US$), February’2021
Figure 4-15: Metformin – Cost of Supply of 30, 90 & 100 Oral Tablets (1000mg) (US$), February’2021
Figure 4-16: Metformin – Cost of Supply of 30, 90 & 100 Oral ER Tablets (750mg) (US$), February’2021

Figure 5-1: Chlorpropamide – Cost of Supply of 30 & 60 Oral Tablets (250mg) (US$), February’2021
Figure 5-2: Chlorpropamide – Cost of Supply of 30 & Per Unit Price of Oral Tablets (100mg) (US$), February’2021
Figure 5-3: Chlorpropamide – Maximum & Minimum Recommended Dose (mg)
Figure 5-4: Glimepiride – FDA Approval & 1st Generic Approval Year
Figure 5-5: US – Glimepiride Patent Approval & Expiration Year
Figure 5-6: Amaryl – Cost of Supply of 100 Tablets & Per Unit Price of 1mg Oral Tablet (US$), February’2021
Figure 5-7: Amaryl – Cost of Supply of 100 Tablets & Per Unit Price of 2mg Oral Tablet (US$), February’2021
Figure 5-8: Amaryl – Cost of Supply of 100 Tablets & Per Unit Price of 4mg Oral Tablet (US$), February’2021
Figure 5-9: Glimepiride – Cost of Supply of 30, 90 & 100 Oral Tablets (1mg) (US$), February’2021
Figure 5-10: Glimepiride – Cost of Supply of 30, 90 & 100 Oral Tablets (2mg) (US$), February’2021
Figure 5-11: Glimepiride – Cost of Supply of 30, 90 & 100 Oral Tablets (4mg) (US$), February’2021

Figure 5-12: Glimepiride – Maximum & Minimum Recommended Dose (mg)
Figure 5-13: Glyburide – FDA Approval & 1st Generic Approval Year
Figure 5-14: DiaBeta – Cost of Supply of 50 Tablets & Per Unit Price of 1.25mg Oral Tablet (US$), February’2021
Figure 5-15: DiaBeta – Cost of Supply of 100 Tablets & Per Unit Price of 2.25mg Oral Tablet (US$), February’2021
Figure 5-16: DiaBeta – Cost of Supply of 100 Tablets & Per Unit Price of 5mg Oral Tablet (US$), February’2021
Figure 5-17: Glynase PresTab – Cost of Supply of 100 Tablets & Per Unit Price of 1.5mg Oral Tablet (US$), February’2021
Figure 5-18: Glynase PresTab – Cost of Supply of 100 & 1000 Tablets of 3mg Oral Tablet (US$), February’2021
Figure 5-19: Glynase PresTab – Cost of Supply of 100 & 500 Tablets of 6mg Oral Tablet (US$), February’2021
Figure 5-20: Glyburide– Cost of Supply of 50 & 100 Tablets of 1.5mg Oral Tablet (US$), February’2021
Figure 5-21: Glyburide– Cost of Supply of 30, 90 & 100 Tablets of 2.5mg Oral Tablet (US$), February’2021
Figure 5-22: Glyburide– Cost of Supply of 30, 90 & 100 Tablets of 5mg Oral Tablet (US$), February’2021
Figure 5-23: Glyburide – Cost of Supply of 100 Tablets & Per Unit Price of 1.5mg Micronized Oral Tablet (US$), February’2021
Figure 5-24: Glyburide – Cost of Supply of 100 & 1000 Tablets of 3mg Micronized Oral Tablet (US$), February’2021
Figure 5-25: Glyburide – Cost of Supply of 100 & 1000 Tablets of 3mg Micronized Oral Tablet (US$), February’2021
Figure 5-26: Glyburide – Maximum & Minimum Recommended Dose of Standard Tablet (mg)
Figure 5-27: Glyburide – Maximum & Minimum Recommended Dose of Micronized Tablet (mg)
Figure 5-28: Glipizide – FDA Approval & 1st Generic Approval Year
Figure 5-29: Glucotrol – Cost of Supply of 100 Tablets & Per Unit Price of 5mg Oral Tablet (US$), February’2021
Figure 5-30: Glucotrol – Cost of Supply of 100 Tablets & Per Unit Price of 10mg Oral Tablet (US$), February’2021

Figure 5-31: Glucotrol XL – Cost of Supply of 30 Tablets & Per Unit Price of 2.5mg Oral Tablet (US$), February’2021
Figure 5-32: Glucotrol XL – Cost of Supply of 100 & 500 Tablets of 5mg Oral Tablet (US$), February’2021
Figure 5-33: Glucotrol XL – Cost of Supply of 100 & 500 Tablets of 10mg Oral Tablet (US$), February’2021
Figure 5-34: Glipizide – Cost of Supply of 30, 90 & 100 Oral Tablets (5mg) (US$), February’2021
Figure 5-35: Glipizide – Cost of Supply of 30, 90 & 100 Oral Tablets (10mg) (US$), February’2021
Figure 5-36: Glipizide – Cost of Supply of 30 Tablets & Per Unit Price of 2.5mg Oral ER Tablet (US$), February’2021
Figure 5-37: Glipizide – Cost of Supply of 100, 500 & 1000 of 5mg Oral ER Tablet (US$), February’2021
Figure 5-38: Glipizide – Cost of Supply of 100, 500 & 1000 of 10mg Oral ER Tablet (US$), February’2021
Figure 5-39: Glipizide – Maximum Recommended Dose by Oral Tablet (mg/day)
Figure 5-40: Tolzamide – Cost of Supply of 90 Tablets & Per Unit Cost of 250mg Tablet (US$), February’2021
Figure 5-41: Tolzamide – Cost of Supply of 100 Tablets & Per Unit Cost of 250mg Tablet (US$), February’2021
Figure 5-42: Tolzamide – Cost of Supply of 100 Tablets & Per Unit Cost of 500mg Tablet (US$), February’2021
Figure 5-43: Tolzamide – Maximum & Minimum Recommended Dose (mg)
Figure 5-44: Tolbutamide – Cost of Supply of 100 Tablets & Per Unit Cost of 500mg Tablet (US$), February’2021
Figure 5-45: Tolbutamide – Maximum & Minimum Recommended Dose (mg)

Figure 6-1: Pioglitazone – FDA Approval & Patent Expiration Year
Figure 6-2: Pioglitazone – FDA Approval & 1st Generic Approval Year
Figure 6-3: Actos – Cost of Supply of 30, 90 & 500 Tablets of 15mg Oral Tablet (US$), February’2021
Figure 6-4: Actos – Cost of Supply of 30 & 500 Tablets of 30mg Oral Tablet (US$), February’2021


Figure 6-5: Actos – Cost of Supply of 30 & 500 Tablets of 45mg Oral Tablet (US$), February’2021
Figure 6-6: Pioglitazone – Cost of Supply of 30, 90 & 500 Tablets of 15mg Oral Tablet (US$), February’2021
Figure 6-7: Pioglitazone – Cost of Supply of 30, 90 & 500 Tablets of 30mg Oral Tablet (US$), February’2021
Figure 6-8: Pioglitazone – Cost of Supply of 30, 90 & 500 Tablets of 45mg Oral Tablet (US$), February’2021
Figure 6-9: Pioglitazone – Maximum & Minimum Recommended Dose (mg)
Figure 6-10: Pioglitazone – Maximum & Minimum Cost of Treatment per Day with Branded & Generic Drugs
Figure 6-11: US - Rosiglitazone Patent Approval & Expiration Year
Figure 6-12: Rosiglitazone – Cost of Supply of 60 Tablets & Per Unit Cost of 2mg Oral Tablet (US$), February’2021
Figure 6-13: Rosiglitazone – Cost of Supply of 30 Tablets & Per Unit Cost of 4mg Oral Tablet (US$), February’2021
Figure 6-14: Rosiglitazone – Maximum & Minimum Recommended Dose (mg)

Figure 7-1: Liraglutide – FDA Approval & Patent Expiration Year
Figure 7-2: Victoza – Cost of Supply of 6ml & Per Unit Cost of Subcutaneous Soltuion (US$), February’2021
Figure 7-3: Victoza – Cost of Supply of 9ml & Per Unit Cost of Subcutaneous Soltuion (US$), February’2021
Figure 7-4: Victoza – Maximum & Minimum Recommended Dose (mg)
Figure 7-5: Global – Victoza Annual Sales (US$ Million), 2018-2020
Figure 7-6: US - Victoza Annual Sales (US$ Million), 2018-2020
Figure 7-7: Victoza – Annual Sales by Region (%), 2019
Figure 7-8: Victoza – Annual Sales by Region (%), 2020
Figure 7-9: US – Exenatide FDA Approval & Patent Expiration Year
Figure 7-10: US – Exenatide FDA Approval by Brand
Figure 7-11: Byetta – Cost of Supply of 1.2ml & Per Unit Cost of 5mcg/0.02ml Subcutaneous Soltuion (US$), February’2021
Figure 7-12: Byetta – Cost of Supply of 2.4ml & Per Unit Cost of 10mcg/0.04ml Subcutaneous Soltuion (US$), February’2021


Figure 7-13: Bydureon – Cost of Supply of 4 & Per Unit Cost of 2mg Subcutaneous Powder (US$), February’2021
Figure 7-14: Bydureon BCise – Cost of Supply of 3.4ml & Per Unit Cost of Subcutaneous Suspension (US$), February’2021
Figure 7-15: Global – Bydureon Annual Sales (US$ Million), 2017-2019
Figure 7-16: US - Bydureon Annual Sales (US$ Million), 2017-2019
Figure 7-17: Bydureon – Annual Sales by Region (%), 2019
Figure 7-18: Global – Bydureon Quarterly Sales (US$ Million), 2020
Figure 7-19: US - Bydureon Quarterly Sales (US$ Million), 2020
Figure 7-20: Bydureon – Annual Sales by Region (%), 2020
Figure 7-21: Global – Byetta Annual Sales (US$ Million), 2017-2019
Figure 7-22: US - Byetta Annual Sales (US$ Million), 2017-2019
Figure 7-23: Byetta – Annual Sales by Region (%), 2019
Figure 7-24: Global – Byetta Quarterly Sales (US$ Million), 2020
Figure 7-25: US - Byetta Quarterly Sales (US$ Million), 2020
Figure 7-26: Byetta – Annual Sales by Region (%), 2020
Figure 7-27: Semaglutide – FDA Approval & Patent Expiration Year
Figure 7-28: Semaglutide – FDA Approval by Brand
Figure 7-29: Ozempic – Cost of Supply of 1.5ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 7-30: Ozempic – Cost of Supply of 3ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 7-31: Ozempic – Maximum & Minimum Recommended Dose (mg)
Figure 7-32: Rybelsus – Cost of Supply of 30 Tablets & Per Unit Price of Oral Tablet (US$), February’2021
Figure 7-33: Rybelsus – Maximum & Minimum Recommended Dose (mg)
Figure 7-34: Global – Ozempic Annual Sales (US$ Million), 2018-2020
Figure 7-35: US - Ozempic Annual Sales (US$ Million), 2018-2020
Figure 7-36: Ozempic – Annual Sales by Region (%), 2019
Figure 7-37: Ozempic – Annual Sales by Region (%), 2020
Figure 7-38: Global – Rybelsus Annual Sales (US$ Million), 2019 & 2020
Figure 7-39: US - Rybelsus Annual Sales (US$ Million), 2019 & 2020
Figure 7-40: Rybelsus – Annual Sales by Region (%), 2020
Figure 7-41: US - Dulaglutide FDA Approval & Patent Exclusivity Year


Figure 7-42: Trulicity – Cost of Supply of 2ml & Per Unit Price of Subcutaneous Solution (US$), February’2021
Figure 7-43: Trulicity – Maximum & Minimum Recommended Dose (mg)
Figure 7-44: Global – Trulicity Annual Sales (US$ Million), 2017-2020
Figure 7-45: US - Lixisenatide FDA Approval & Patent Expiration Year
Figure 7-46: Adlyxin – Cost of Supply 6ml & Per Unit Price of Subcutaneous Kit/Solution (US$), February’2021
Figure 7-47: Adlyxin – Recommended Initial Dose & Maintenance Dose (mcg)

Figure 8-1: US - Sitagliptin FDA Approval & Patent Exclusivity Year
Figure 8-2: Januvia – Cost of Supply of 30, 90 & 100 Oral Tablets (US$), February’2021
Figure 8-3: Januvia –Recommended Initial Dose & Subsequent Reductions (mg)
Figure 8-4: Global – Januvia Annual Sales (US$ Million), 2017-2019
Figure 8-5: US - Januvia Annual Sales (US$ Million), 2017-2019
Figure 8-6: Januvia – Annual Sales by Region (%), 2019
Figure 8-7: Global - Januvia Quarterely Sales (US$ Million), 2020
Figure 8-8: US - Saxagliptin FDA Approval & Patent Expiration Year
Figure 8-9: Onglyza – Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 8-10: Onglyza – Cost of Supply of 90 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 8-11: Onglyza – Cost of Daily, Monthly & Annual Treatment (US$)
Figure 8-12: Global – Onglyza Annual Sales (US$ Million), 2017-2019
Figure 8-13: US - Onglyza Annual Sales (US$ Million), 2017-2019
Figure 8-14: Onglyza – Annual Sales by Region (%), 2019
Figure 8-15: Global – Onglyza Quarterly Sales (US$ Million), 2020
Figure 8-16: US - Onglyza Quarterly Sales (US$ Million), 2020
Figure 8-17: Onglyza – Annual Sales by Region (%), 2020
Figure 8-18: US - Linagliptin FDA Approval & Patent Expiration Year
Figure 8-19: Tradjenta – Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 8-20: Tradjenta – Cost of Supply of 90 & Per Unit Price of Oral Tablet (US$), February’2021


Figure 8-21: Tradjenta – Cost of Supply of 100 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 8-22: Tradjenta – Cost of Daily, Monthly & Annual Treatment (US$)
Figure 8-23: US – Alogliptin Patent Approval & Expiration Year
Figure 8-24: US - Alogliptin FDA Approval & Patent Expiration Year
Figure 8-25: Nesina – Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 8-26: Nesina –Recommended Initial Dose & Subsequent Reductions (mg)

Figure 9-1: US – Canagliflozin Patent Approval & Expiration Year
Figure 9-2: Invokana – Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 9-3: Invokana – Cost of Supply of 90 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 9-4: Invokana – Maximum & Minimum Recommended Dose (mg)
Figure 9-5: Global – Invokana Annual Sales (US$ Million), 2017-2019
Figure 9-6: US - Invokana Annual Sales (US$ Million), 2017-2019
Figure 9-7: Invokana – Annual Sales by Region (%), 2019
Figure 9-8: Global – Invokana Quarterly Sales (US$ Million), 2019 & 2020
Figure 9-9: US - Invokana Quarterly Sales (US$ Million), 2019 & 2020
Figure 9-10: Invokana – Annual Sales by Region (%), 2020
Figure 9-11: US - Ertugliflozin FDA Approval & Patent Exclusivity Year
Figure 9-12: US – Ertugliflozin Patent Approval & Expiration Year
Figure 9-13: Steglatro – Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 9-14: Steglatro – Cost of Supply of 90 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 9-15: Steglatro – Cost of Supply of 500 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 9-16: Steglatro – Maximum & Minimum Recommended Dose (mg)
Figure 9-17: US – Ertugliflozin Patent Approval & Expiration Year
Figure 9-18: Jardiance – Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 9-19: Jardiance – Cost of Supply of 90 & Per Unit Price of Oral Tablet (US$), February’2021

Figure 9-20: Jardiance – Maximum & Minimum Recommended Dose (mg)
Figure 9-21: Global – Jardiance Annual Sales (US$ Million), 2017-2020
Figure 9-22: US - Linagliptin FDA Approval & Patent Expiration Year
Figure 9-23: US – Dapagliflozin Patent Approval & Expiration Year
Figure 9-24: Farxiga – Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 9-25: Farxiga – Maximum & Minimum Recommended Dose (mg)
Figure 9-26: Global – Farxiga Annual Sales (US$ Million), 2017-2019
Figure 9-27: US - Farxiga Annual Sales (US$ Million), 2017-2019
Figure 9-28: Farxiga – Annual Sales by Region (%), 2019
Figure 9-29: Global – Farxiga Quarterly Sales (US$ Million), 2020
Figure 9-30: US - Farxiga Quarterly Sales (US$ Million), 2020
Figure 9-31: Farxiga – Annual Sales by Region (%), 2020

Figure 10-1: Repaglinide – Cost of Supply of 100 & Per Unit Price of Oral Tablet of 0.5mg (US$), February’2021
Figure 10-2: Repaglinide – Cost of Supply of 30, 100 & 500 Oral Tablets of 1mg (US$), February’2021
Figure 10-3: Repaglinide – Cost of Supply of 100 & 500 Oral Tablets of 2mg (US$), February’2021
Figure 10-4: Repaglinide – Maximum & Minimum Recommended Dose (mg)
Figure 10-5: Nateglinide – Cost of Supply of 30, 90 & 100 Oral Tablets of 60mg (US$), February’2021
Figure 10-6: Nateglinide – Cost of Supply of 30, 90 & 100 Oral Tablets of 120mg (US$), February’2021

Figure 11-1: US – Miglitol FDA Approval & Generic Availability Year
Figure 11-2: Glyset – Cost of Supply of 100 & Per Unit Price of 25mg Oral Tablet (US$), February’2021
Figure 11-3: Glyset – Cost of Supply of 100 & Per Unit Price of 50mg Oral Tablet (US$), February’2021
Figure 11-4: Glyset – Cost of Supply of 100 & Per Unit Price of 100mg Oral Tablet (US$), February’2021
Figure 11-5: Miglitol – Cost of Supply of 100 & Per Unit Price of 25mg Oral Tablet (US$), February’2021

Figure 11-6: Miglitol – Cost of Supply of 100 & Per Unit Price of 50mg Oral Tablet (US$), February’2021
Figure 11-7: Miglitol – Cost of Supply of 100 & Per Unit Price of 100mg Oral Tablet (US$), February’2021
Figure 11-8: Miglitol – Maximum & Minimum Recommended Dose (mg)
Figure 11-9: Acarbose – Cost of Supply of 90, 100 & 1000 Oral Tablets of 25mg (US$), February’2021
Figure 11-10: Acarbose – Cost of Supply of 90, 100 & 1000 Oral Tablets of 50mg (US$), February’2021
Figure 11-11: Acarbose – Cost of Supply of 90, 100 & 1000 Oral Tablets of 100mg (US$), February’2021
Figure 11-12: Acarbose – Maximum Recommended Dose by Weight (mg)

Figure 12-1: US – Metformin/Sitagliptin FDA Approval by Brand
Figure 12-2: US – Janumet Patent Approval & Expiration Year
Figure 12-3: US – Janumet XR Patent Approval & Expiration Year
Figure 12-4: Janumet – Cost of Supply of 60, 180 & 1000 Oral Tablets (US$), February’2021
Figure 12-5: Janumet XR – Cost of Supply of 60, 180 & 1000 Oral Tablets (US$), February’2021
Figure 12-6: Global – Janumet Annual Sales (US$ Million), 2017-2019
Figure 12-7: US - Janumet Annual Sales (US$ Million), 2017-2019
Figure 12-8: Janumet – Annual Sales by Region (%), 2019
Figure 12-9: Global - Janumet Quarterely Sales (US$ Million), 2020
Figure 12-10: US – Duetact FDA Approval & Generic ApprovalYear
Figure 12-11: US – Duetact Patent Approval & Expiration Year
Figure 12-12: Duetact – Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 12-13: Glimepiride/Pioglitazone – Cost of Supply of 30 & Per Unit Price of 2mg-30mg Oral Tablet (US$), February’2021
Figure 12-14: Glimepiride/Pioglitazone – Cost of Supply of 30 & Per Unit Price of 4mg-30mg Oral Tablet (US$), February’2021
Figure 12-15: US – Glyburide/Metformin FDA Approval & Generic Availability Year
Figure 12-16: Glucovance – Cost of Supply of 100 & Per Unit Price of Oral Tablet (US$), February’2021

Figure 12-17: Glyburide/Metformin – Cost of Supply of 100 & 500 Oral Tablets of 1.25mg (US$), February’2021
Figure 12-18: Glyburide/Metformin – Cost of Supply of 100 & 500 Oral Tablets of 2.5mg (US$), February’2021
Figure 12-19: Glyburide/Metformin – Cost of Supply of 100 & 500 Oral Tablets of 2.5mg (US$), February’2021
Figure 12-20: Glyburide/Metformin – Maximum & Minimum Recommended Dose (mg)
Figure 12-21: US – Dapagliflozin/Metformin Patent Approval & Expiration Year
Figure 12-22: Xigduo – Cost of Supply of 30 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 12-23: US – Synjardy Patent Approval & Expiration Year
Figure 12-24: US – Synjardy XR Patent Approval & Expiration Year
Figure 12-25: Synjardy – Cost of Supply of 60 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 12-26: Synjardy – Cost of Supply of 180 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 12-27: Glipizide/Metformin – Cost of Supply of 100 & Per Unit Price of 2.5mg-250mg Oral Tablet (US$), February’2021
Figure 12-28: Glipizide/Metformin – Cost of Supply of 100 & Per Unit Price of 2.5mg-500mg Oral Tablet (US$), February’2021
Figure 12-29: Glipizide/Metformin – Cost of Supply of 100 & Per Unit Price of 5mg-500mg Oral Tablet (US$), February’2021
Figure 12-30: US – Linagliptin/Metformin FDA Approval by Brand
Figure 12-31: US – Jantadueto Patent Approval & Expiration Year
Figure 12-32: Jantadeuto – Cost of Supply of 60 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 12-33: Jantadeuto – Cost of Supply of 180 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 12-34: Jantadeuto XR – Cost of Supply of 60 & Per Unit Price of 2.5mg-1000mg Oral Tablet (US$), February’2021
Figure 12-35: Jantadeuto XR – Cost of Supply of 180 & Per Unit Price of 2.5mg-1000mg Oral Tablet (US$), February’2021
Figure 12-36: Jantadeuto XR – Cost of Supply of 30 & Per Unit Price of 2.5mg-1000mg Oral Tablet (US$), February’2021


Figure 12-37: Jantadeuto XR – Cost of Supply of 90 & Per Unit Price of 5mg-1000mg Oral Tablet (US$), February’2021
Figure 12-38: US – Metformin/Pioglitazone FDA Approval & Generic Availability Year
Figure 12-39: US – ActoPlus Met Patent Approval & Expiration Year
Figure 12-40: ActoPlus Met – Cost of Supply of 60 & Per Unit Price of Oral Tablet (US$), February’2021
Figure 12-41: ActoPlus Met – Cost of Supply of 180 & Per Unit Price ofOral